Clinical Findings of Colchicine Toxicity

Introduction to Colchicine Toxicity

Colchicine toxicity is a serious and potentially fatal complication that manifests in three sequential phases, beginning with gastrointestinal symptoms, progressing to multiorgan failure, and potentially ending with recovery or death 1, 2

Colchicine toxicity can occur due to exceeding recommended doses, with maximum recommended doses being 3 mg daily in adults and 2 mg daily in children 1, 2
Liver or renal failure can also lead to colchicine toxicity, as the elimination half-life can increase up to sevenfold in liver cirrhosis 1
Drug interactions with medications metabolized by cytochrome 3A4, such as macrolides, ketoconazole, ritonavir, verapamil, ciclosporin, and statins, can increase colchicine blood levels by 200-300% 1, 2

Gastrointestinal symptoms, including severe abdominal pain and diarrhea, predominate in the first phase of colchicine toxicity 1, 2
Multiorgan failure, including bone marrow failure, renal insufficiency, and adult respiratory distress syndrome, develops in the second phase 1, 2
Recovery phase, which can last several weeks, involves resolution of organ failure and rebound leukocytosis 1

Elevated liver enzymes and creatine phosphokinase (CPK) are common laboratory findings in colchicine toxicity 1, 3
Coagulation abnormalities are also a concern in colchicine toxicity 1

Patients with pre-existing renal impairment and liver disease are at high risk of colchicine toxicity 1, 2
Patients taking medications that interact with colchicine are also at increased risk 1

Regular monitoring of liver enzymes and CPK is recommended for patients on colchicine 1, 3
Adherence to recommended dosing guidelines, dose reduction in patients with renal or hepatic impairment, and avoidance of interacting medications can help prevent colchicine toxicity 1, 2
Patient education about signs and symptoms of toxicity is also crucial in preventing colchicine toxicity 1

The European League Against Rheumatism (EULAR) guidelines recommend monitoring liver enzymes regularly in patients with FMF treated with colchicine, and reducing the dose if liver enzymes are elevated greater than twofold the upper limit of normal, with further investigation into the cause 4
Response, toxicity, and compliance should be monitored every 6 months in all patients on colchicine, with more frequent monitoring initially to assess tolerability 4, 5

In pediatric patients, elevated liver function tests may reflect colchicine side effects, particularly during viral infections, while in adult patients, elevated liver enzymes may indicate inadequate control of underlying inflammation rather than drug toxicity 6
The combination of hepatic and renal impairment creates a high risk of colchicine-induced toxicity, including rhabdomyolysis, and requires careful monitoring and potential dose reduction 5

Dose reduction should be considered for patients with severe hepatic impairment, and concomitant administration of drugs metabolized by cytochrome 3A4 should be avoided to prevent increased colchicine blood levels 5
If liver enzymes rise above 2-fold the upper limit of normal, the dose should be reduced and alternative causes investigated 4

Colchicine should be discontinued immediately if the patient develops progressive muscle weakness, severe diarrhea, acute worsening of liver function tests, or cytopenias, and it is essential not to assume elevated liver enzymes are always due to colchicine, but to investigate for underlying liver disease or inadequately controlled inflammatory disease 6, 5